Patent application number | Description | Published |
20080249241 | Microgel-Containing Thermoplastic Elastomer Composition - The present invention relates to a composition comprising thermoplastic materials and crosslinked microgels which are not crosslinked by high-energy radiation, processes for its preparation, its use for the production of thermoplastically processable shaped articles and shaped articles produced from the composition. | 10-09-2008 |
20080275152 | Halogen-free, flame-retardant polyurethane foams - The present invention relates to flame-retardant polyurethane foams which comprise, as flame retardant, halogen-free bisphosphonates free from hydroxy groups. | 11-06-2008 |
20100041780 | HALOGEN-FREE, FLAME-RETARDANT POLYURETHANE FOAMS WITH LOW SCORCH LEVEL - The present invention relates to halogen-free flame-retardant polyurethane foams with low scorch level which comprise, as flame retardant, a mixture composed of at least one polyaryl phosphate and of at least one monoaryl phosphate, and also to a method for the production of these foams, and to their use. | 02-18-2010 |
20120058358 | Flame-retardant timber materials - The present invention relates to timber materials rendered flame-retardant by using halogen-free organophosphorus compounds, to means and processes for producing these materials, and also to their use. | 03-08-2012 |
20140024734 | HALOGEN-FREE POLY(ALKYLENE PHOSPHATES) - The present invention relates to halogen-free oligomer mixtures of poly(alkylene phosphates), production of these and use as flame retardants, and also to flame-retardant polyurethanes comprising halogen-free oligomer mixtures as flame retardants. | 01-23-2014 |
20150080276 | PHOSPHORIC ESTER PREPARATIONS WITH REDUCED HYGROSCOPICITY - The present invention relates to phosphoric ester preparations with reduced hygroscopicity, to use of these as flame retardants and hydraulic fluids, and to polyurethanes which comprise the phosphoric ester preparations of the invention. | 03-19-2015 |
Patent application number | Description | Published |
20100297700 | Antibodies to TNF Alpha - Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids. | 11-25-2010 |
20120237496 | PROTEASE VARIANTS - The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta. | 09-20-2012 |
20120321619 | ANTI-C4.4A ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 12-20-2012 |
20140322220 | Anti-FGFR2 Antibodies and Uses Thereof - The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 10-30-2014 |
Patent application number | Description | Published |
20100137583 | Peptidomimetic protease inhibitors - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 06-03-2010 |
20120064034 | Peptidomimetic protease inhibitors - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 03-15-2012 |
20120282219 | PEPTIDOMIMETIC PROTEASE INHIBITORS - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 11-08-2012 |
20140294763 | PEPTIDOMIMETIC PROTEASE INHIBITORS - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 10-02-2014 |
Patent application number | Description | Published |
20090171698 | PROVIDING HUMAN CAPITAL MANAGEMENT SOFTWARE APPLICATION AS ENTERPRISE SERVICES - Methods and apparatus, including systems and computer program products, for a service architecture design that provides enterprise services having human capital management functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described. | 07-02-2009 |
20100070555 | ARCHITECTURAL DESIGN FOR TIME RECORDING APPLICATION SOFTWARE - Methods, systems, and apparatus, including computer program products, for implementing a software architecture design for a software application implementing time recording. The application is structured as multiple process components interacting with each other through service interfaces, and multiple service operations, each being implemented for a respective process component. The process components include a Project Processing process component that supports the management of projects, a Time and Labor Management process component that supports the management of employees timekeeping and work planning, an Accounting process component that records relevant business transactions, a payroll processing process component that supports the execution and monitoring of payroll processes, and a Goods and Service Acknowledgement process component that receives a confirmation from an employee of goods received or services rendered. | 03-18-2010 |
20100153158 | PROVIDING PROJECT MANAGEMENT SOFTWARE APPLICATION AS ENTERPRISE SERVICES - Methods and apparatus, including systems and computer program products, for a service architecture design that provides enterprise services having project management functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described. | 06-17-2010 |
20140214934 | Composition Engine as a Service - A method includes: providing a composition engine as a service configured to receive requests from multiple service consumers using any of multiple service consumer protocols; receiving a first request in the composition engine as a service conforming to a service consumer protocol from a service consumer operated by a customer; generating a second request to each of one or more provider systems, the second request conforming to a provider system protocol, the composition engine as a service configured to generate requests conforming to any of multiple provider system protocols; receiving, by the composition engine as a service, information from the provider system, and adapting the received information to conform to the service consumer protocol; and exposing, by the composition engine as a service, a web service that makes the adapted information available to the service consumer. | 07-31-2014 |
20140297713 | INTEGRATED DEVELOPMENT ENVIRONMENT FOR HETEROGENEOUS CLIENT/SERVER ENVIRONMENTS - The present disclosure describes methods, systems, and computer program products providing an integrated development environment for client/server environments. One computer-implemented method includes reading a derived business application data model (BADM) associated with a business application into an integrated development environment (IDE), defining a client application data model (CADM) for a client application, defining at least one data mapping rule (DMR) to map at least data translations between the BADM and the CADM, developing the client application based upon at least the CADM, developing at least one web service based upon the BADM, CADM, and the at least one DMR, generating the client application and the at least one web service, and deploying the client application, the at least one web service, and the at least one DMR. | 10-02-2014 |
20150066788 | SOCIAL MEDIA INTEGRATION PLATFORM - Techniques for using a social media integration platform include receiving a request from a business system to interact with a social media system executing on a social media platform; integrating, using the social media integration platform, the request between the business system and the social media system by translating the request from the business system to a social media request compliant with the social media platform, wherein the social media integration platform is configured to translate requests between at least one type of business system and a plurality of different types of social media platforms; and sending the social media request to the social media system. | 03-05-2015 |